Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641) - MK-3475-641 - Merck Sharp & Dohme Corp.See more
Prostate Imaging Using MRI +/- Contrast Enhancement - PRIME - University College, LondonSee more
Kidney cancer
Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC - SAMETA - AstraZenecaSee more